Hyperici herba extract interaction with artificial lipid bilayers

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 10, 2004, Pages 1283-1289

  Neagoe, Ioana ^a   Macri, Beatrice M ^a   Flonta, Maria Luisa ^a  

^a UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICUM EXTRACT; PHOSPHATIDYLCHOLINE;

ARTICLE; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRIC CAPACITANCE; ELECTRIC CONDUCTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERICUM; LIPID COMPOSITION; LIPID MEMBRANE; MEMBRANE CONDUCTANCE; NERVE CELL EXCITABILITY; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

HYPERICUM PERFORATUM;

EID: 5644271679     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357044292     Document Type: Article

References (57)

1. Albert, D., Zundorf, I., Dingermann, T., Muller, W. E., Steinhilber, D., Werz, O. (2002) Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol. 64: 1767-1775
2. Alkhenizan, A. (2001) Comparison of St John's wort and imipramine. Finding must be treated with caution. BMJ 322: 493
3. Avato, P., Raffo, F., Guglielmi, G., Vitali, C., Rosato, A. (2004) Extracts from St John's Wort and their antimicrobial activity. Phytother. Res. 18: 230-232
4. Barnes, J., Anderson, L. A., Phillipson, J. D. (2001) St John's wort (Hypericum perforatum L. ): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol. 53 583-600
5. Barnes, J. P., Freed, J. H. (1998) Dynamics and ordering in mixed model membranes of dimyristoylphosphatidylcholine and dimyristoylphosphatidylserine: a 250-GHz electron spin resonance study using cholestane. Biophys. J. 75: 2532-2546
6. Behnke, K., Jensen, G. S., Graubaum, H. J., Gruenwald, J. (2002) Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv. Ther. 19: 43-52
7. Bork, P. M., Bacher, S., Schmitz, M. L., Kaspers, U., Heinrich, M. (1999) Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med. 65: 297-300
8. Butterweck, V. (2003) Mechanism of action of St John's wort in depression: what is known? CNS Drugs 17: 539-562
9. Butterweck, V., Bockers, T., Korte, B., Wittkowski, W., Winterhoff, H. (2002) Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res. 930: 21-29
10. Cervo, L., Rozio, M., Ekalle-Soppo, C. B., Guiso, G., Morazzoni, P., Caccia, S. (2002) Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berlin) 164: 423-428
11. Chen, Y., Ferguson, S. S., Negishi, M., Goldstein, J. A. (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther. 308: 495-501
12. Eckert, G. P., Muller, W. E. (2001) Effects of hyperforin on the fluidity of brain membranes. Pharmacopsychiatry 34: S22-S25
13. Ernst, E., Rand, J. I., Barnes, J., Stevinson, C. (1998) Adverse effects profile of the herbal antidepressant St. John's wort ( Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 54: 589-594
14. Feigenson, G. W., Buboltz, J. T. (2001) Ternary phase diagram of dipalmitoyl-PC/dilauroyl-PC/cholesterol: nanoscopic domain formation driven by cholesterol. Biophys. J. 80: 2775-2788
15. +-ATPase from kidney on black lipid membranes. EMBO J. 4: 3079-3085
16. Fischer, L., Szellas, D., Radmark, O., Steinhilber, D., Werz, O. (2003) Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 17 949-951
17. Fornal, C. A., Metzler, C. W., Mirescu, C., Stein, S. K., Jacobs, B. L. (2001) Effects of standardized extracts of St. John's wort on the single-unit activity of serotonergic dorsal Raphe neurons in awake cats: comparisons with fluoxetine and sertraline. Neuropsychopharmacology 25: 858-870
18. Gobbi, M., Moia, M., Pirona, L., Morizzoni, P., Mennini, T. (2001) In vitro binding studies with two Hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 34: S45-S48
19. Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., Kliewer, S. A. (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60: 427-431
20. Hanke, W., Schlue, W. R. (1993) Planar lipid bilayers. Methods and applications. Academic Press, San Diego
21. Harrer, G., Hubner, W. D., Podzuweit, H. (1994) Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J. Geriatr. Psychiatry Neurol. 7 S24-S28
22. Heilmann, J., Winkelmann, K., Sticher, O. (2003) Studies on the antioxidative activity of phloroglucinol derivatives isolated from hypericum species. Planta Med. 69: 202-206
23. Hostanska, K., Reichling, J., Bommer, S., Weber, M., Saller, R. (2003) Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur. J. Pharm. Biopharm. 56: 121-132
24. Hunt, E. J., Lester, C. E., Lester, E. A., Tackett, R. L. (2001) Effect of St. John's wort on free radical production. Life Sci. 69: 181-190
25. Johnson, D., Ksciuk, H., Woelk, H., Sauerwein-Giese, E., Frauendorf, A. (1994) Effects of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers. J. Geriatr. Psychiatry Neurol. 7: S44-S46
26. Kaehler, S. T., Sinner, C., Chatterjee, S. S., Philippu, A. (1999) Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci. Lett. 262: 199-202
27. Kaufeler, R., Meier, B., Brattstrom, A. (2001) Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview. Pharmacopsychiatry 34: S49-S50
28. Kientsch, U., Burgi, S., Ruedeberg, C., Probst, S., Honegger, U. E. (2001) St. John's wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry 34: S56-S60
29. Komoroski, B. J., Zhang, S., Cai, H., Hutzler, J. M., Frye, R., Tracy, T. S., Strom, S. C., Lehmann, T., Ang, C. Y., Cui, Y. Y., Venkataramanan, R. (2004) Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 32: 512-518
30. Krishtal, O., Lozovaya, N., Fisunov, A., Tsintsadze, T., Pankratov, Y., Kopanitsa, M., Chatterjee, S. S. (2001) Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 34: S74-S82
31. Langosch, J. M., Zhou, X. Y., Heinen, M., Kupferschmid, S., Chatterjee, S. S., Noldner, M., Walden, J. (2002) St John's wort ( Hypericum perforatum) modulates evoked potentials in guinea pig hippocampal slices via AMPA and GABA receptors. Eur. Neuropsychopharmacol. 12: 209-216
32. Lecrubier, Y., Clerc, G., Didi, R., Kieser, M. (2002) Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry 159 1361-1366
33. Mouristen, O. G., Jorgensen, K., Honger, T. (1995) Permeability of lipid bilayers near the phase transition. In: Disalvo, E. A., Simon, S. A. (eds) Permeability and stability of lipid bilayers. CRC Press, Boca Raton, pp 137-160
34. Movileanu, L., Neagoe, I., Flonta, M. L. (2000) Interaction of the antioxidant flavonoid quercetin with planar lipid bilayers. Int. J. Pharm. 205: 135-146
35. Muller, W. E., Singer, A., Wonnemann, M. (2001) Hyperforin - antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34: S98-S102
36. Muruganandam, A. V., Bhattacharya, S. K., Ghosal, S. (2001) Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study. Indian J. Exp. Biol. 39: 1302-1304
37. Nahrstedt, A., Butterweck, V. (1997) Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30: 129-134
38. Payk, T. R. (1994) Treatment of depression. J. Geriatr. Psychiatry Neurol. 7: S3-S5
39. Peebles, K. A., Baker, R. K., Kurz, E. U., Schneider, B. J., Kroll, D. J. (2001) Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort ( Hypericum perforatum). Biochem. Pharmacol. 62: 1059-1070
40. Radhakrishnan, A., McConnell, H. M. (1999) Condensed complexes of cholesterol and phospholipids. Biophys. J. 77: 1507-1517
41. Roz, N., Rehavi, M. (2003) Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci. 73: 461-470
42. Schempp, C. M., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Kiss, J., Termeer, C. C., Gilb, B., Kaufmann, T., Borner, C., Sleeman, J. P., Simon, J. C. (2002a) Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 21: 1242-1250
43. Schempp, C. M., Muller, K. A., Winghofer, B., Schopf, E., Simon, J. C. (2002b) [St. John's wort (Hypericum perforatum L.). A plant with relevance for dermatology]. Hautarzt 53: 316-321
44. Schwarz, D., Kisselev, P., Roots, I. (2003) St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res. 63: 8062-8068
45. Simons, K., Ikonen, E. (1997) Functional rafts in cell membranes. Nature 387: 569-572
46. Timoshanko, A., Stough, C., Vitetta, L., Nathan, P. J. (2001) A preliminary investigation on the acute pharmacodynamic effects of hypericum on cognitive and psychomotor performance. Behav. Pharmacol. 12: 635-640
47. Turnheim, K., Gruber, J., Wachter, C., Ruiz-Gutierrez, V. (1999) Membrane phospholipid composition affects function of potassium channels from rabbit colon epithelium. Am. J. Physiol. 277: C83-C90
48. Volp, A. (2001) Comparison of St John's Wort and imipramine. Sensitivity of assay is questionable. BMJ 322: 493-494
49. Vorbach, E. U., Arnoldt, K. H., Hubner, W. D. (1997) Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30: 81-85
50. Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., Lambert, M. H., Kliewer, S. A., Redinbo, M. R. (2003) 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42 1430-1438
51. Weitman, H., Roslaniec, M., Frimer, A. A., Afri, M., Freeman, D., Mazur, Y., Ehrenberg, B. (2001) Solvatochromic effects in the electronic absorption and nuclear magnetic resonance spectra of hypericin in organic solvents and in lipid bilayers. Photochem. Photobiol. 73: 110-118
52. Wheatley, D. (1997) LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 30: 77-80
53. Whiskey, E., Werneke, U., Taylor, D. (2001) A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int. Clin. Psychopharmacol. 16 239-252
54. Widy-Tyszkiewicz, E., Piechal, A., Joniec, I., Blecharz-Klin, K. (2002) Long term administration of Hypericum perforatum improves spatial learning and memory in the water maze. Biol. Pharm. Bull. 25: 1289-1294
55. Woelk, H. (2000) Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 321 536-539
56. 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188-197
57. Xu, X., London, E. (2000) The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. Biochemistry 39: 843-849